Azepane

Azepane

SCHEMBL714889

C1CCCNCC1.O=C(O)O

nearest known ligand 0.64

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

GSK3AGSK3BIMPA1

The experimentally established mechanism targets of Azepane. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.64
SMN1; SMN2 Q16637 2/20 0.44
CXCR4 P61073 1/20 0.44
CA2 P00918 2/20 0.42
CHKA P35790 1/20 0.42
TSHR P16473 2/20 0.41
GABRP O00591 1/20 0.41
GABRD O14764 1/20 0.41
GABRA1 P14867 1/20 0.41
GABRB1 P18505 1/20 0.41
GABRG2 P18507 1/20 0.41
GABRB3 P28472 1/20 0.41
GABRA5 P31644 1/20 0.41
GABRA3 P34903 1/20 0.41
GABRA2 P47869 1/20 0.41
GABRB2 P47870 1/20 0.41
GABRA4 P48169 1/20 0.41
GABRE P78334 1/20 0.41
PMP22 Q01453 1/20 0.41
GABRA6 Q16445 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Piperidine SCHEMBL4577836 1.00 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2CXCR4CA2CHKA
Piperidine SCHEMBL720107 1.00 ALDH1A1 (0.64) ALDH1A1SMN1; SMN2CXCR4CA2CHKA
Azepane SCHEMBL20740115 0.97 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2CXCR4CA2CHKA
Azepane SCHEMBL940042 0.97 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2CXCR4CA2CHKA
Pyrrolidine SCHEMBL712847 0.96
Piperidine SCHEMBL5875101 0.90 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2CXCR4CA2CHKA
Piperidine SCHEMBL2483462 0.90 ALDH1A1 (0.60) ALDH1A1SMN1; SMN2CXCR4CA2CHKA
Azetidine SCHEMBL7551428 0.89
Piperidine SCHEMBL10332243 0.87 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2CXCR4CA2CHKA
Piperidine SCHEMBL9400727 0.87 ALDH1A1 (0.56) ALDH1A1SMN1; SMN2CXCR4CA2CHKA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070225380-A1 Parakeratosis Inhibitor and Skin Preparation for External use SHISEIDO COMPANY LTD. (JP) 2007-09-27 US claimed
EP-1688126-A1 PARAKERATOSIS INHIBITOR AND EXTERNAL COMPOSITION FOR SKIN SHISEIDO COMPANY LIMITED (JP) 2006-08-09 EP claimed
EP-3444089-B1 PREPREG, FIBER-REINFORCED COMPOSITE MATERIAL AND SURFACE-MODIFIED REINFORCING FIBERS TEIJIN LTD (JP) 2024-02-28 EP disclosed
CN-115280556-A Conductive material dispersion liquid, positive electrode for lithium ion secondary battery using same, and method for producing lithium ion secondary battery 御国色素株式会社 2022-11-01 CN disclosed
US-11352472-B2 Prepreg, fiber-reinforced composite material and surface-modified reinforcing fibers TEIJIN LIMITED (JP) 2022-06-07 US disclosed
US-9299483-B2 Method for manufacturing transparent conductive film INKTEC CO., LTD. (KR) 2016-03-29 US disclosed
US-9290844-B2 Method for preparing metallic thin film INKTEC CO., LTD. (KR) 2016-03-22 US disclosed
US-8586638-B2 Parakeratosis inhibitor and skin preparation for external use SHISEIDO COMPANY, LTD (JP) 2013-11-19 US disclosed
US-20130118786-A1 Method for Manufacturing Transparent Conductive Film and Transparent Conductive Film Manufactured Thereby INKTEC CO., LTD. (KR) 2013-05-16 US disclosed
US-20120253064-A1 PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE SHISEIDO COMPANY, LTD. (JP) 2012-10-04 US disclosed
EP-2491980-A2 Parakeratosis inhibitor and skin preparation for external use SHISEIDO COMPANY LIMITED (JP) 2012-08-29 EP disclosed
EP-2491981-A2 Parakeratosis inhibitor and external composition for skin SHISEIDO COMPANY LIMITED (JP) 2012-08-29 EP disclosed
US-20120053243-A1 PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE SHISEIDO COMPANY, LTD. (JP) 2012-03-01 US disclosed
US-20110318481-A1 Method for Preparing Metallic Thin Film INKTEC CO., LTD. (KR) 2011-12-29 US disclosed
WO-2009075520-A1 A METHOD FOR FABRICATING BLACKENED CONDUCTIVE PATTERNS INKTEC CO., LTD. (KR) 2009-06-18 WO disclosed
US-20070225380-A1 Parakeratosis Inhibitor and Skin Preparation for External use SHISEIDO COMPANY LTD. (JP) 2007-09-27 US disclosed
EP-1688126-A1 PARAKERATOSIS INHIBITOR AND EXTERNAL COMPOSITION FOR SKIN SHISEIDO COMPANY LIMITED (JP) 2006-08-09 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120053243-A1 PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE CUTA, HPN, DNPEP ALDH1A1 3008/4885SMN1; SMN2 4072/4885CXCR4 4314/4885
US-20120253064-A1 PARAKERATOSIS INHIBITOR AND SKIN PREPARATION FOR EXTERNAL USE CUTA, HPN, PRSS1 ALDH1A1 3879/4885SMN1; SMN2 4493/4885CXCR4 4674/4885
US-20070225380-A1 Parakeratosis Inhibitor and Skin Preparation for External use CUTA, HPN, DNPEP ALDH1A1 3008/4885SMN1; SMN2 4072/4885CXCR4 4314/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.